home / About us / Research Store / Latest reports / Services / NEWS & MEDIA / contact us

Reports

Ideas That Generate Results

Reports by Industry
Reports by Company
Global Immune Checkpoint Inhibitors Market Outlook 2022

Global Immune Checkpoint Inhibitors Market Outlook 2022

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Mar, 2020| No. of Pages : 130

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 1800.00
CD-ROM Mail Delivery
US$ 2000.00
Hard Copy Mail Delivery
US$ 2000.00
Electronic Access - Multi-User License
US$ 2500.00
List of Figures:
 
Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030 
Figure 4-3: Global - Population above 60 Years (Billion), 2015 & 2050
Figure 4-4: Expected Combination Regimen Launches in Oncology
Figure 5-1: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2016-2022
Figure 6-1: Global - Yervoy Market (Million US$), 2012-2018
Figure 6-2: Global - Tecentriq Market (Million US$), 2016 & 2017
Figure 6-3: Global - Bavencio Market (Million US$), 2017-2021
Figure 6-4: Global - Imfinzi Market (Million US$), 2017
Figure 6-5: Global - Opdivo Market (Million US$), 2014-2016
Figure 6-6: Global - Keytruda Market (Million US$), 2014-2016
Figure 7-1: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-2: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-3: Lung Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-4: Lung Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-5: Melanoma - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-6: Melanoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-7: Lymphoma - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-8: Lymphoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-9: Leukemia - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-10: Leukemia - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-11: Other Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-12: Other Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 8-1: Immuno-Oncology Funding by Product Type (Billion, US$), 2015-2016
Figure 8-2: Major Investors in Immuno-Oncology Market (2015-2016)
Figure 8-3: Bristol-Myers Squibb and Merck & Co. - Strategic Collaborations
Figure 10-1: Global - Immune Checkpoint Inhibitors Pipeline Analysis by Product Type (%), 2016
Figure 10-2: Global – Immune Checkpoint Inhibitors Pipeline Analysis by Phase (%), 2016
Figure 11-1: F. Hoffmann-La Roche AG - Sales by Business Segments (%), 2016
Figure 11-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Segments (%), 2016
Figure 11-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Geography (%), 2016
Figure 11-4: Novartis AG - Breakup of Sales by Business Segment (%), 2016
Figure 11-5: Novartis AG - Breakup of Pharmaceuticals Division Sales by Segment (%), 2016
Figure 11-6: Novartis AG - Breakup of Sales by Geography (%), 2016
Figure 11-7: Bristol Myers Squibb - Revenue by Business Segments (%), 2016
Figure 11-8: Bristol Myers Squibb - Revenue by Geography (%), 2016
Figure 11-9: Merck & Co., Inc. - Revenue by Business Segments (%), 2016
Figure 11-10: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segments (%), 2016 
Figure 11-11: Merck & Co., Inc. - Revenue by Geography (%), 2016
Figure 11-12: AstraZeneca Plc - Revenue by Business Segments (%), 2016
Figure 11-13: AstraZeneca Plc - Revenue by Geography (%), 2016
Figure 11-14: Pfizer Inc - Revenue by Business Segments (%), 2016
Figure 11-15: Pfizer Inc - Revenue by Geography (%), 2016
 
List of Tables:
 
Table 4-1: Immune Checkpoint Inhibitors - Late Stage Research Pipeline
Table 6-1: Ongoing Trials for Yervoy
Table 6-2: Ongoing Trials for Opdivo
Table 6-3: Ongoing Trials for Keytruda
Table 7-1: Global - Oncology Incidence by Geography (‘000), 2015 & 2020
Table 8-1: Selected Immuno-Oncology and Targeted Therapy Combinations
Table 9-1: Strategic Collaborations in the Immune Checkpoint Inhibitors Market
Table 10-1: Active Immune Checkpoint Inhibitors Programs 
Table 10-2: Global - Immune Checkpoint Inhibitors Product Pipeline
Table 11-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2014-2016
Table 11-2: Genentech, Inc. - Commercialized Immune Checkpoint Inhibitors
Table 11-3: Genentech, Inc. – Product Pipeline
Table 11-4: CureTech Ltd. - Product Pipeline
Table 11-5: NewLink Genetics Corporation- Key Financials (Million US$), 2014-2016
Table 11-6: NewLink Genetics Corporation - Product Pipeline
Table 11-7: Novartis AG - Key Financials (Billion US$), 2014-2016
Table 11-8: Novartis AG - Product Pipeline
Table 11-9: Bristol Myers Squibb - Key Financials (Million US$), 2014-2016
Table 11-10: Bristol Myers Squibb - Commercialized Immune Checkpoint Inhibitors
Table 11-11: Bristol Myers Squibb - Product Pipeline
Table 11-12: Merck & Co., Inc. - Key Financials (Million US$), 2014-2016
Table 11-13: Merck & Co., Inc. - Commercialized Immune Checkpoint Inhibitors
Table 11-14: Merck & Co., Inc. - Product Pipeline
Table 11-15: AstraZeneca Plc - Key Financials (Million US$), 2014-2016
Table 11-16: AstraZeneca Plc - Commercialized Immune Checkpoint Inhibitors
Table 11-17: AstraZeneca Plc - Product Pipeline
Table 11-18: Pfizer Inc - Key Financials (Billion US$), 2014-2016
Table 11-19: Pfizer Inc - Commercialized Immune Checkpoint Inhibitors 
Table 11-20: Pfizer Inc - Product Pipeline
Table 11-21: Ono Pharmaceutical Co., Ltd. - Key Financials (Million US$), FY2014-FY2016
Table 11-22: Ono Pharmaceutical Co., Ltd. - Commercialized Immune Checkpoint Inhibitors
Table 11-23: Ono Pharmaceutical Co., Ltd. - Product Pipeline
Table 11-24: EMD Serono, Inc. - Commercialized Immune Checkpoint Inhibitors
Table 11-25: EMD Serono, Inc. - Product Pipeline
Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.

Not readable? Change text.